Adriana Carrá
A5036671827- Multiple Sclerosis Research Studies
- Systemic Sclerosis and Related Diseases
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- SARS-CoV-2 and COVID-19 Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Systemic Lupus Erythematosus Research
- Reproductive System and Pregnancy
- Long-Term Effects of COVID-19
- Viral Infections and Immunology Research
- Biosimilars and Bioanalytical Methods
- Digital Imaging for Blood Diseases
- Migration, Health and Trauma
- Pregnancy and Medication Impact
- Health Systems, Economic Evaluations, Quality of Life
- Telemedicine and Telehealth Implementation
- Aging, Health, and Disability
- Vaccine Coverage and Hesitancy
- Autoimmune and Inflammatory Disorders Research
- Retinal and Optic Conditions
- Pharmaceutical Economics and Policy
- Bacillus and Francisella bacterial research
- Polyomavirus and related diseases
- Herpesvirus Infections and Treatments
- Cancer Research and Treatment
Hospital Británico de Buenos Aires
2015-2024
Fundacion Favaloro Hospital Universitario
2020-2024
Favaloro University
2018-2022
Hospital Británico
2003-2022
Instituto de Neurología Cognitiva
2018-2022
Guglielmo da Saliceto Hospital
2019
Favaloro Foundation
2017
Background and objective: We explored which clinical biochemical variables predict conversion from clinically isolated syndrome (CIS) to definite multiple sclerosis (CDMS) in a large international cohort. Methods: Thirty-three centres provided serum samples 1047 CIS cases with at least two years’ follow-up. Age, sex, presentation, T2-hyperintense lesions, cerebrospinal fluid (CSF) oligoclonal bands (OCBs), CSF IgG index, cell count, 25-hydroxyvitamin D3 (25-OH-D), cotinine titres against...
Background: The placebo-controlled phase of the PreCISe study showed that glatiramer acetate delayed onset clinically definite multiple sclerosis (CDMS) in patients with isolated syndrome and brain lesions on MRI. Objective: To compare effects early versus treatment open-label PreCISe. Methods: Patients a suggestive MS unifocal manifestation ≥2 T2-weighted were randomized to receive 20 mg/d (early-treatment, n=198) or placebo (delayed-treatment, n=211) for 36 months until conversion CDMS,...
Background The influence of pregnancy on Multiple Sclerosis (MS) has been extensively studied but such Latin American women with MS not characterized. Our objective was to describe the course and birth outcome in Argentinean patients evolution during after delivery. Method We used a retrospective design eight centers Argentina administered survey definite (Mc Donald) pregnancies or onset. contacted 355 which 81 met inclusion criteria. recorded 141 pregnancies. Results Involuntary abortion...
Switching treatment may be beneficial in patients with relapsing–remitting multiple sclerosis (RRMS) who respond inadequately to first‐line immunomodulatory therapy. The objective of this study was evaluate clinical outcomes after switching such patients. This prospective longitudinal observational included 114 RRMS failed monotherapy and were switched treatments 3 years. Every months, underwent a full neurological examination. Outcome compared between the 3‐year Before Switch After periods....
There are few studies reporting multiple sclerosis prevalence rates in the Buenos Aires region, Argentina (latitude 34°S) (between 12–18.5/100 000 inhabitants), and no have been performed larger region between parallels 36° 55°S. The aim of this study is to determine clinical features residents Argentine Patagonia. Four cities from were selected for study, giving a sample population 417 666 inhabitants (~24% total Patagonia population). 1 st March 2002 was determined as day. Patients...
The idiopathic inflammatory demyelinating disease (IIDD) spectrum has been investigated among different populations, and the results have indicated a low relative frequency of neuromyelitis optica (NMO) multiple sclerosis (MS) cases in whites (1.2%-1.5%), increasing Mestizos (8%) Africans (15.4%-27.5%) living areas MS prevalence. South America (SA) was colonized by Europeans from Iberian Peninsula, their miscegenation with natives slaves resulted significant racial mixing. current study...
BackgroundNeuromyelitis optica spectrum disorders (NMOSD) is an increasing diagnostic and therapeutic challenge in Latin America (LATAM). Despite the heterogeneity of this population, ethnic socioeconomic commonalities exist, epidemiologic studies from region have had a limited geographic population outreach. Identification some aspects entire are lacking.ObjectivesTo determine ethnic, clinical characteristics, utilization tools types therapy for patients with NMOSD American...
Studies suggest that patients with relapsing-remitting multiple sclerosis (RRMS) who do not benefit from other disease-modifying treatments (DMTs) may converting to glatiramer acetate (GA). COPTIMIZE was a 24-month observational study designed assess the disease course of GA 20 mg daily another DMT. Eligible had converted and received prior DMT for 3–6 months, depending on reasons conversion. Patients were assessed at baseline 6, 12, 18, 24 months. In total, 672 148 centers worldwide...
Scarce data exist about multiple sclerosis (MS) prevalence in South America. The objective of the study is to determine MS a high populated area from Argentina (Greater Buenos Aires Metropolitan area) using capture-recapture methodology.Greater generic denomination that refers megalopolis comprised by autonomous city and surrounding conurbation province Aires. was carried out taking July 1996 as month. We used method estimate cross matching registries four Centers.A total 803 were obtained...
The 2024 McDonald Criteria now include the optic nerve as fifth topography for dissemination in space. Optical coherence tomography (OCT) is a valuable biomarker diagnosis, prognosis and monitoring of multiple sclerosis (MS). A panel MS neurologists from 19 centres across 9 Latin American (LATAM) countries discussed OCT use, access, standardized protocols research potential. They found inequities access between private (80%) public healthcare (44%). Only had protocols, 50% which followed...
To date, there are no data available on the safety of COVID-19 vaccines in Latin American patients with Multiple Sclerosis (MS).Characterize (LATAM) (pwMS).A cross-sectional study between February 1, 2021, and April 30, 2021. Individuals MS from LATAM countries were invited to participate a self-administered web-based survey, through patient organizations region.393 vaccinated pwMS 10 different included. The administered were: inactivated virus (IVV) 38.2% patients, adenovirus vector (AdV)...
We performed an observational, retrospective analysis of outcome in a sequential cohort patients with relapsing–remitting multiple sclerosis (RRMS) Argentina. Patients treated for 16 months interferon β ‐1a (Avonex ® ; 30 μ g intramuscularly, once week), (Rebif 44 subcutaneously, thrice weekly), ‐1b (Betaferon 250 every other day) or glatiramer acetate (Copaxone 20 mg subcutaneously daily) were compared non‐treated group patients. The different treatment groups similar baseline demographic...